KRAS and neoplasm: In conclusion, in these real-life and population-based cohorts reflecting the background population, we did not detect any significant or clinically relevant differences in patient characteristics and tumor outcomes between patients with KRAS-G12C tumors compared to those with other KRAS mutations.